Research on GLP-1 analog peptides, including semaglutide, tirzepatide, and retatrutide, is being conducted to explore their effects on obesity. These peptides are being studied for their potential metabolic, cardiovascular, and renal benefits, as well as their potential risks, such as interactions and venous thromboembolism. Some of these medications are already being used, possibly through unregulated online markets, despite their status and potential risks.